Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma? (Q35210415)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma?	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

Europe PubMed Central

Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma? (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

based on heuristic

inferred from title

author name string

Stephen M Ansell

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1309-1315

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Interleukin 12: a new clinical player in cytokine therapy

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Inhibition of angiogenesis in vivo by interleukin 12.

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Assignment of genes encoding a unique cytokine (IL12) composed of two unrelated subunits to chromosomes 3 and 5

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000083325

21 January 2018

Identifiers

10.1080/1042819031000083325

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35210415&oldid=1969985834"